France's Sanofi has agreed to buy U.S.-based Blueprint Medicines Corporation for over $9 billion to boost its position in ...

Sanofi and Stagecoach Performing Arts are excited to introduce a unique partnership. Selected through a UK-wide audition process, four talented teens living with autoimmune Type 1 diabetes (aT1D) have ...

France's Sanofi has agreed to buy US-based Blueprint Medicines Corp. for over $9 billion to boost its position in rare ...

Sanofi has scrapped its collaboration with IGM Biosciences, eliminating the biotech’s last program in the process. IGM responded by laying off 80% of its staff and closing most of its lab and ...

We came across a bullish thesis on Sanofi (SNY) on Substack by Business Model Mastery. In this article, we will summarize the bulls’ thesis on SNY. Sanofi (SNY)'s share was trading at $51.06 as ...

Recent research from Sanofi highlights the significant impact of Type 1 Diabetes on those living with the condition The song, "Rise Up," shares their experiences of living with the condition and will ...

MORRISTOWN, N.J. and CAMBRIDGE, Mass., May 14, 2025 /PRNewswire/ -- Sanofi today announces its intention to invest at least $20 billion in the United States through 2030. The expected investment ...

PARIS, France — French pharmaceutical firm Sanofi said Wednesday it plans to invest at least $20 billion into its operations in the United States through 2030 to expand both research and ...

Morristown-based Sanofi will spend $20 billion on its U.S. operations through 2030. It also has a Massachusetts presence. Sanofi has roughly 1,900 employees in Morristown at the M Station ...

Sanofi plans to boost its U.S.-based research and development and manufacturing investments to at least $20 billon over the next five years. In a May 14 press release, the French multinational ...

Sanofi said it will invest at least $20 billion in the US through 2030, joining other pharmaceutical companies boosting their American operations as President Donald Trump threatens to impose ...

Investing.com -- Moody’s Ratings has upgraded the long-term issuer rating and senior unsecured ratings of Sanofi (NASDAQ:SNY) from A1 to Aa3. The outlook for the company has been revised from ...